35 results about "Cancer relapse" patented technology

The present invention provides a method for preparing a reference model for cancer relapse prediction that provides higher resolution grading than Gleason score alone. The method encompasses obtaining from different individuals a plurality of prostate carcinoma tissue samples of known clinical outcome representing different Gleason scores; selecting a set of signature genes having an expression pattern that correlates positively or negatively in a statistically significant manner with the Gleason scores; independently deriving a prediction score that correlates gene expression of each individual signature gene with Gleason score for each signature gene in said plurality of prostate carcinoma tissue samples; deriving a prostate cancer gene expression (GEX) score that correlates gene expression of said set of signature genes with the Gleason score based on the combination of independently derived prediction scores in the plurality of prostate cancer tissue samples; and correlating said GEX score with the clinical outcome for each prostate carcinoma tissue sample. A set of signature genes is provided that encompasses all or a sub-combination of GI_2094528, KIP2, NRG1, NBL1, Prostein, CCNE2, CDC6, FBP1, HOXC6, MKI67, MYBL2, PTTG1, RAMP, UBE2C, Wnt5A, MEMD, AZGP1, CCK, MLCK, PPAP2B, and PROK1. Also provided a methods for predicting the probability of relapse of cancer in an individual and methods for deriving a prostate cancer gene expression (GEX) score for a prostate carcinoma tissue sample obtained from an individual.

The present invention provides a method for preparing a reference model for cancer relapse prediction that provides higher resolution grading than Gleason score alone. The method encompasses obtaining from different individuals a plurality of prostate carcinoma tissue samples of known clinical outcome representing different Gleason scores; selecting a set of signature genes having an expression pattern that correlates positively or negatively in a statistically significant manner with the Gleason scores; independently deriving a prediction score that correlates gene expression of each individual signature gene with Gleason score for each signature gene in said plurality of prostate carcinoma tissue samples; deriving a prostate cancer gene expression (GEX) score that correlates gene expression of said set of signature genes with the Gleason score based on the combination of independently derived prediction scores in the plurality of prostate cancer tissue samples; and correlating said GEX score with the clinical outcome for each prostate carcinoma tissue sample. A set of signature genes is provided that encompasses all or a sub-combination of GI_2094528, KIP2, NRG1, NBL1, Prostein, CCNE2, CDC6, FBP1, HOXC6, MKI67, MYBL2, PTTG1, RAMP, UBE2C, Wnt5A, MEMD, AZGP1, CCK, MLCK, PPAP2B, and PROK1. Also provided a methods for predicting the probability of relapse of cancer in an individual and methods for deriving a prostate cancer gene expression (GEX) score for a prostate carcinoma tissue sample obtained from an individual.

The present invention provides a method for preparing a reference model for cancer relapse prediction that provides higher resolution grading than Gleason score alone. The method encompasses obtaining from different individuals a plurality of prostate carcinoma tissue samples of known clinical outcome representing different Gleason scores; selecting a set of signature genes having an expression pattern that correlates positively or negatively in a statistically significant manner with the Gleason scores; independently deriving a prediction score that correlates gene expression of each individual signature gene with Gleason score for each signature gene in said plurality of prostate carcinoma tissue samples; deriving a prostate cancer gene expression (GEX) score that correlates gene expression of said set of signature genes with the Gleason score based on the combination of independently derived prediction scores in the plurality of prostate cancer tissue samples; and correlating said GEX score with the clinical outcome for each prostate carcinoma tissue sample. A set of signature genes is provided that encompasses all or a sub-combination of GI_2094528, KIP2, NRG1, NBL1, Prostein, CCNE2, CDC6, FBP1, HOXC6, MKI67, MYBL2, PTTG1, RAMP, UBE2C, Wnt5A, MEMD, AZGP1, CCK, MLCK, PPAP2B, and PROK1. Also provided a methods for predicting the probability of relapse of cancer in an individual and methods for deriving a prostate cancer gene expression (GEX) score for a prostate carcinoma tissue sample obtained from an individual.

The invention relates to correlation between long noncoding RNA (ribonucleic acid) H19 and drug resistance of cancers to platinum chemotherapeutics and relates to usages of medicaments, which are capable of reducing and / or inhibiting expression of the long noncoding RNA H19 in cancer cells, in preparation of medicines for treatment or prevention of cancers and medicines for reducing drug resistance of the cancers to the platinum chemotherapeutics. The invention further relates to usages of medicaments, which are capable of detecting expression of the long noncoding RNA H19, in preparation of detection kits, wherein the detection kits are used for diagnosis of carcinogenesis or predication of cancer relapse and used for predication, detection or diagnosis of drug resistance of cancer patients to the platinum chemotherapeutics. The invention further relates to pharmaceutical compositions comprising the medicaments. The cancers refer to cancers which can be treated with the platinum chemotherapeutics, and preferably, the cancers refer to ovarian cancers.

The invention relates to a method for detecting hsa_circ_0007986 as a novel biomarker in serum of a patient with esophageal cancer. The method mainly comprises digital PCR detection of the biomarker shown as SEQ ID NO:1. Primers used in digital PCR amplification comprise a forward primer shown as SEQ ID NO:2 and a reverse primer shown as SEQ ID NO:3. Hsa_circ_0007986 can be used for preparing a diagnosis reagent and / or drug for esophageal cancer. The method for detecting the esophageal cancer is safe and noninvasive, and even asymptomatic population has high acceptability for the detection; hsa_circ_0007986 is high in accuracy and has higher sensitivity and specificity for the esophageal cancer, is suitable for early screening of the esophageal cancer and serving as the biomarker for prognosis of the esophageal cancer, and cancer relapse and treatment effect are monitored.

The invention provides an application of the ACTL6A gene to preparation of a medicine for treating liver cancer or preventing relapse of liver cancer after surgery. Experiments show that when corresponding protein coded by the ACTL6A gene is highly expressed in a cell nucleus, the postoperative cancer relapse rate is increased. Through various known dosage methods, the expression of the corresponding protein coded by the ACTL6A gene is restrained. Thus, the EMT function of liver cancer cells in the human body is effectively prevented, the transferring possibility of liver cancer cells in the human body is reduced, survival time of a patient is prolonged after surgery, and transferring and relapse are reduced.

Provided is an a combination therapy including a radiosensitizing agent and radiation, and being effective to inhibit proliferation of cancer stem cells. Further provided is a combination which includes a radiosensitizing agent and radiation, and effectively reduces incidence of at least one of cancer relapse and metastatic cancer in a subject having a cancer, wherein the cancer includes cancer stem cells. Also provided are anthraquinone derivatives for use as radiosensitizing agents in combination with radiations, the combination therapy being cancer specific. Further, the radiosensitizing agents were found to be cancer specific, namely, some being more effective against a cancer type as compared to others.

The invention discloses an implanted cancer relapse real-time monitoring system. The monitoring system comprises an in-vivo implantation assembly and an in-vitro assembly, wherein the in-vivo implantation assembly can convert concentration information of circulating cell-free nucleic acids in a tissue fluid into transmittal digital information and transmit the digital information to the in-vitro assembly in a wireless transmission manner; the in-vitro assembly analyzes the received circulating cell-free nucleic acid information and informs a user of the implanted cancer relapse real-time monitoring system of paying attention to cancer relapse danger in an information display or warning manner. The implanted cancer relapse real-time monitoring system can monitor a molecular marker, circulating cell-free nucleic acids, of cancer relapse / transfer in real time and can detect the cancer relapse danger in an early stage of cancer relapse, so that a patient suffering from cancer relapse can be treated in time.

Disclosed is a method and system for determining cancer therapy effects via imaging omics features, including a synthesis unit which is used for matching the patient positioning image with the timingimages in the treating process, wherein the data on the positioning image is mapped to the timing images in the treating process; the selected part on the timing image is cut into multiple corresponding area of interest; an acquisition unit used for extrating imaging omics features with stability on the patient image; and an analysis unit used for assessing the treating effects of the patients based on the changes of the imaging omics feature parameters in the areas of interest along with the treatment progress. The scheme has the following advantages of high stability and repeatability; the timing image optic features changes sharply along with the treatment gradation and accumulated dose; the early individuation prediction of cancer recurrence and metastasis or radiation damage to the normal tissue are obtained, so the control probability of the cancer is improved while the radiation damage to the normal tissue and cancer relapse are reduced.

The present invention provides methods of treating cancer in a subject, preventing or delaying relapse to a cancer in a subject in remission, prolonging remission from cancer, increasing survival, anddecreasing or alleviating cancer symptoms comprising a) administering histamine dihydrochloride and an inhibitor of the Programmed cell Death protein 1 (PD-1) / Programmed Death Ligand 1 (PD-L1) or b)administering an agent that decreases reactive oxygen species (ROS) optionally, together with a histamine receptor agonist. The present invention also provides methods of predicting the efficacy of acancer treatment based on a re-distribution of cytotoxic T cells, frequency of NK cells, or other biochemical changes, and related methods of preventing relapse to cancer and for prolonging remissionfrom a cancer. Related kits and compositions are also provided.

The present invention provides methods and compositions for enhancing efficacy of anti-hormone treatment, or for preventing cancer relapse or progression following treatment. The invention also provides methods for re-sensitizing or sensitizing treatment resistant cancer cells or patients with treatment-refractory cancer cells to continuing or starting anti-hormone treatment. Further provided in the invention are methods for prognosis or diagnosis of anti-hormone treatment effect or likelihood of cancer relapse or metastasis following anti-hormone treatment.

The invention relates to the field of medicine, in particular to a polypeptide capable of inhibiting tight-junction protein and preventing and treating a cancer relapse and transfer of the postoperative breast cancer. The brand new sequence of the polypeptide is LNLSSTLASGKDATGSYPTLMV. The polypeptide can inhibit proliferation and migration of breast cancer cells in an in-vitro mode, the survival rate of tumor-bearing mice is increased in an in-vivo test, and the polypeptide has the potential new medicine development value.

The invention discloses a traditional Chinese medicine capable of tonifying qi and blood. The traditional Chinese medicine is composed of the following components in parts by weight: 5 to 10 parts of ginseng, 5 to 10 parts of pilos antler, 10 to 20 parts of wolfberry, and 10 to 20 parts of red sage root. The pharmaceutical effect and health care effect of the traditional Chinese medicine are fully exerted. The traditional Chinese medicine can enhance the human immunity, and can also reduce blood sugar, blood fat, and blood pressure, prevent cancer, cancer cell spread, and cancer relapse, improve myocardial blood supply, resist arteriosclerosis, enhance immunity, and delay cell aging.

The present invention relates to the use of a CD24 protein for preventing or treating relapse of a cancer in a subject. The present invention also relates to the use of a CD24 protein for reducing cancer stem cell activity.

Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate RSK signaling. Some aspects of the invention relate to the use of N-desmethyl ruboxistaurin to inhibit RSK. Some aspects of the invention provide methods of using N-desmethyl ruboxistaurin in the treatment of subjects with cancer, including breast cancer, ovarian cancer, prostate cancer, lung cancer, hepatocellular carcinoma, colorectal cancer, melanoma, osteosarcoma, myeloproliferative neoplasms, leukemia, and bladder cancer. The disclosed methods extend beyond disease treatment, including supportive care during radiation chemotherapy and prevention of cancer relapse. N-desmethyl ruboxistaurin administration, alone or in combination with other cancer therapies, inhibits RSK and shows a safety profile that supports its long-term use.

The invention discloses an implanted cancer relapse real-time monitoring system. The monitoring system comprises an in-vivo implantation assembly and an in-vitro assembly, wherein the in-vivo implantation assembly can convert concentration information of circulating cell-free nucleic acids in a tissue fluid into transmittal digital information and transmit the digital information to the in-vitro assembly in a wireless transmission manner; the in-vitro assembly analyzes the received circulating cell-free nucleic acid information and informs a user of the implanted cancer relapse real-time monitoring system of paying attention to cancer relapse danger in an information display or warning manner. The implanted cancer relapse real-time monitoring system can monitor a molecular marker, circulating cell-free nucleic acids, of cancer relapse / transfer in real time and can detect the cancer relapse danger in an early stage of cancer relapse, so that a patient suffering from cancer relapse can be treated in time.

Methods of determining cancer progression or cancer relapse in a subject at risk for cancer progression or cancer relapse, the methods comprising: obtaining a sample from said subject; measuring the level of VEGFR1+ hematopoietic progenitor cells (HPCs) and / or VEGFR2+ endothelial progenitor cells (EPCs) in said sample; and taking additional samples and conducting additional measurements of HPCs and / or EPCs at one or more later time points. From the measurements, it can be determined whether there is a surge in the level of HPCs and / or EPCs in at least one later measurement, relative to an earlier measurement. A surge in the level of HPCs and / or EPCs indicates increased risk of progression or relapse of said subject's cancer.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for replenishing qi, enriching blood, tonifying spleen and nourishing kidney as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 2 to 12 parts of radix angelicae sinensis, 5 to 20 parts of radix codonopsis, 5 to 20 parts of radix astragali seu hedysari, 2 to 12 parts of rhizoma atractylodis macrocephalae, 2 to 15 parts of poria cocos, 3 to 13 parts of colla corii asini, 3 to 13 parts of tortoise-shell glue, 2 to 12 parts of herba cistanche, 5 to 15 parts of radix rehmanniae praeparata, 3 to 15 parts of rhizoma polygonati, 3 to 13 parts of herba epimedii, 2 to 12 parts of fructus crataegi, 5 to 15 parts of arillus longan, 2 to 12 parts of fructus ligustri lucidi, 2 to 6 parts of fructus schisandrae chinensis and 1 to 5 parts of cortex cinnamomi. The traditional Chinese medicine composition has the main effects of replenishing qi, enriching blood, tonifying spleen and nourishing kidney, is used for rehabilitation after cancer surgery or chemotherapy and used for resisting cancer relapse, is particularly used for patients with spleen and kidney deficiency type cachexia after cancer surgery or chemotherapy, and improves the problems of emaciation, insomnia, inappetence, mental fatigue and tiredness and the like of the patients with the patients with the spleen and kidney deficiency type cachexia after cancer surgery or chemotherapy.

Conventional CAR-T cell therapies have shown a significant success in the treatment of hematological cancers and lymphoma. However, this technique still has several problems, including cancer recurrence. Herein, a scalable technical platform is described to produce synthetic viscoelastic activated cells (SynVAC) with programmable mechanical and chemical activity as artificial antigen presenting cells (aAPC). The disclosure presented herein shows that the viscoelastic properties of the described SynVAC have great beneficial effects on expansion of T cells. For example, SynVAC exhibits robust improvements in T cell expansion, T memory stem cell (TMSC) formation, chimeric antigen receptor (CAR) transduction efficiency, tumor killing efficiency, and long-term in vivo persistence of CAR-T cells compared to conventional rigid or elastic microspheres.

The invention relates to a digital droplet polymerase chain reaction method that simultaneously detects and can quantify relative levels of multiple tumor associated antigens associated with relapse of a cancer after prior treatment. It does not require invasive bone marrow sampling or biopsy and permits rational targeting based on the types of TAAs expressed by relapsing cancer cells.

The present invention pertains to a method of treating cancer or its relapse in mammals by employing platinum based compounds. More particularly, the present invention provides to enhance immunity in a mammal, using a compound of Formula I and / or Formula II, preferably Compound 1 or its derivative, salt, tautomeric form, isomer, polymorph, solvate, or intermediates thereof. The method of inducing an immune response in a mammal is mediated through immune memory. The present invention also provides for such platinum based compounds and their use in treating cancer, metastasis or cancer relapse.

The invention relates to a method for detecting hsa_circ_0007986 as a novel biomarker in serum of a patient with esophageal cancer. The method mainly comprises digital PCR detection of the biomarker shown as SEQ ID NO:1. Primers used in digital PCR amplification comprise a forward primer shown as SEQ ID NO:2 and a reverse primer shown as SEQ ID NO:3. Hsa_circ_0007986 can be used for preparing a diagnosis reagent and / or drug for esophageal cancer. The method for detecting the esophageal cancer is safe and noninvasive, and even asymptomatic population has high acceptability for the detection; hsa_circ_0007986 is high in accuracy and has higher sensitivity and specificity for the esophageal cancer, is suitable for early screening of the esophageal cancer and serving as the biomarker for prognosis of the esophageal cancer, and cancer relapse and treatment effect are monitored.

The invention relates to a preparation method and application of a medicine for preventing cancer relapse, the medicine is mainly suitable for the conditions that after cancer radiotherapy / chemotherapy, a patient is recovered, but the cancer patient suffers from environment change, body change, disease relapse after radiotherapy / chemotherapy and the like, the medicine is mainly prepared from Chinese herbal medicines as main materials and vitamin AD and an inhibitor as auxiliary materials, and the medicine is free of toxic and side effects. The invention relates to main traditional Chinese medicines including coix seeds, Chinese dates, platycodon grandiflorum, cassia twigs, motherwort, poria cocos, charred triplet and vitamin AD. The traditional Chinese medicines are decocted, dried and compressed, different auxiliary medicines are added at the same time, uniform mixing is performed again, and dry powder is formed. The traditional Chinese medicine composition can be taken in the chemoradiotherapy process and can also be independently taken after chemoradiotherapy rehabilitation.

Provided are uses of an agent capable of reducing and / or inhibiting the expression of long non-coding RNA H19 in cancer cells in the preparation of a medicine for treating or preventing cancers, and in the preparation of a medicine for reducing the resistance of cancers to the platinum-based chemotherapeutic drug. Also provided is a use of an agent capable of detecting the expression of a long non-coding RNA H19 in the preparation of a test kit, the test kit being used for diagnosing the occurrence of cancers or predicting a cancer relapse, and for predicting, detecting or diagnosing the resistance to the platinum-based chemotherapeutic drug of a cancer patient.

The invention discloses an antigen epitope peptide coded by mRNA and fused in phosphatidylinositol anchoring protein and application of the antigen epitope peptide, and belongs to the field of biological medicine. The antigen epitope peptide comprises a MUC1 (1TR)-CD24 molecule and a MUC1 (1TR, 13aa)-CD24 molecule; the MUC1 (1TR)-CD24 molecule comprises an MUC1 signal peptide, an MUC1 extracellular domain containing one MUC1 VNTR sequence, a CD24 polypeptide and a phosphatidylinositol anchoring signal peptide; the MUC1 (1TR, 13aa)-CD24 molecule contains MUC1 signal peptide, MUC1 (1TR, 13aa) sequence, CD24 polypeptide and phosphatidylinositol anchoring signal peptide, the process is simple, the sequence is controllable, CAR-T cell amplification can be efficiently activated, CAR-T cells can be stimulated to secrete anti-tumor cell factors, and the MUC1 (1TR, 13aa)-CD24 molecule has important medical value in preparation of drugs for treating cancers or preventing cancer relapse.

The invention belongs to the technical field of biomedicine, and particularly relates to application of AAV9-CPEB3 in preparation of a medicine for treating gastric cancer. Experiments show that when expression of corresponding protein coded by the CPEB3 gene is reduced in cytoplasm, the postoperative cancer recurrence probability of a patient is increased. Through various known administration modes, expression up-regulation of corresponding protein coded by the CPEB3 gene is realized, so proliferation of gastric cancer cells in a human body after an operation is effectively prevented, the metastasis opportunity of the gastric cancer cells in the human body is reduced, the survival quality of a patient after the operation is thus improved, postoperative rehabilitation is improved, and gastric cancer relapse is prevented.

Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate CDK4 / 6 signaling. The invention encompasses methods for administering N-desmethyl ruboxistaurin to subjects in need, particularly those with a history of cancer or currently experiencing breast cancer, liposarcoma, lung cancer, glioblastoma, melanoma, pancreatic cancer, prostate cancer, colon cancer, ovarian cancer, colorectal cancer, bladder cancer, hepatocellular carcinoma, osteosarcoma, germ cell tumors, advanced solid tumors, lymphoma, leukemia and other hematologic malignancies. The disclosed methods extend beyond disease treatment, including supportive care during radiation chemotherapy and prevention of cancer relapse. N-desmethyl ruboxistaurin administration, alone or in combination with other cancer therapies, is effective in modulating CDK4 / 6 signaling while mitigating toxicity associated with other treatments.

The present invention discloses a smart device used for cancer relapse real-time dynamic monitoring. The smart device comprises an in vivo implantation assembly and an in vitro assembly, wherein the in vivo implantation assembly can convert tumor markers protein information in the blood to transmittable digital information which is transmitted to the in vitro assembly in a wireless transmission manner, and the in vitro assembly analyzes the received protein information and notifies an implantable cancer relapse real-time monitoring system user to notice the danger of cancer relapse by information display and alarm manners. The smart device provided by the present invention can monitor molecular marker protein of cancer relapse / metastasis in real time, and can detect the danger of cancer relapse at the early stage, thereby enabling the relapsed patient to acquire timely treatment.

Methods and compositions which provide a gene expression-based prognostic signature of cancer relapse and prediction of metastatic cancer are described, and in particular methods to predict colorectal cancer (CRC) recurrence and chemosensitivity.